Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
临床药代动力学促进临床药代动力学和药效学的持续发展，以改善药物治疗，并促进临床药理学和治疗学的研究生教育。药代动力学是研究药物在体内处置的一门学科，是药物开发和合理使用的一个组成部分。药代动力学原理的知识和应用导致加速药物开发、成本有效的药物使用和减少不良反应和药物相互作用的频率。
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00741-9
Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-018-0727-5
What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00791-z
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00766-0
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00756-2
Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00750-8
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00759-z
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00765-1
SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00801-0
Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00812-x
Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00827-4
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00778-w
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00840-7
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00841-6
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-018-00734-0
Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00854-1
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00842-5
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00837-2
Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00846-1
Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00790-0
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00856-z
Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00737-5
Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00767-z
A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00844-3
A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00825-6
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00758-0
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00843-4
A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00831-8
Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00793-x
Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00780-2
Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00782-0
Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00786-w
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00830-9
Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00834-5
Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-018-0729-3
An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00798-6
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00794-w
Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00773-1
Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00792-y
Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00797-7
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00826-5
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00755-3
Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00838-1
Update on Therapeutic Protein–Drug Interaction: Information in Labeling
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00810-z
Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00851-4
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00849-y
Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00853-2
Authors’ Reply to Nicolas: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00781-1
Correction to: Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00835-4
A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
来源期刊：Clinical PharmacokineticsDOI：10.1007/s40262-019-00803-y
